GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY) exploring broader applications beyond weight management, including heart disease and sleep apnea treatments.
Yahoo Finance Health Reporter Anjalee Khemlani dives into the details, analyzing the outlook for GLP-1 drugs as markets head into 2025.
Also, catch Anjalee Khemlani highlight the three biggest catalysts for the healthcare industry expected in the new year.
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
This post was written by Angel Smith
